Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

A David Rodrigues

Showing results (81-90 of 132) with videos related to

Pageof 14
Sort By:
Clinical Pharmacology and Therapeutics|December 16, 2022
Effect of Hepatic Impairment on OATP1B Activity: Quantitative Pharmacokinetic Analysis of Endogenous Biomarker and Substrate DrugsJian Lin, Emi Kimoto, Shinji Yamazaki, et al.
The Journal of Pharmacology and Experimental Therapeutics|January 29, 2005
Selective inhibition of dog hepatic CYP2B11 and CYP3A12Ping Lu, Suresh B Singh, Brian A Carr, et al.
British Journal of Clinical Pharmacology|May 20, 2014
Validation of 4β-hydroxycholesterol and evaluation of other endogenous biomarkers for the assessment of CYP3A activity in healthy subjectsSreeneeranj Kasichayanula, David W Boulton, Wen-Lin Luo, et al.
The Journal of Pharmacology and Experimental Therapeutics|January 13, 2018
Organic Anion Transporter 2 Mediates Hepatic Uptake of Tolbutamide, a CYP2C9 Probe DrugYi-An Bi, Sumathy Mathialagan, Laurie Tylaska, et al.
Drug Metabolism and Disposition: the Biological Fate of Chemicals|June 1, 2012
Evaluation of six proton pump inhibitors as inhibitors of various human cytochromes P450: focus on cytochrome P450 2C19Tatyana Zvyaga, Shu-Ying Chang, Cliff Chen, et al.
Journal of Clinical Pharmacology|January 12, 2019
Use of Physiologically Based Pharmacokinetic Modeling to Identify Physiological and Molecular Characteristics Driving Variability in Axitinib Exposure: A Fresh Approach to Precision Dosing in OncologyMichael J Sorich, Fayzah Mutlib, Madelé van Dyk, et al.
Journal of Extracellular Vesicles|May 28, 2026
Extracellular Vesicles as Enabling Biomarkers for New Approach Methodologies to Support the US Food and Drug Administration Modernization Act 3.0Andrew Rowland, Carl Kirkpatrick, A David Rodrigues, et al.
Drug Metabolism and Disposition: the Biological Fate of Chemicals|February 14, 2018
Comparison of Proteomic Quantification Approaches for Hepatic Drug Transporters: Multiplexed Global Quantitation Correlates with Targeted Proteomic QuantitationAnna Vildhede, Chuong Nguyen, Brian K Erickson, et al.
Drug Metabolism and Disposition: the Biological Fate of Chemicals|December 17, 2013
Expression and characterization of cynomolgus monkey cytochrome CYP3A4 in a novel human embryonic kidney cell-based mammalian systemSindhuja Selvakumar, Priyadeep Bhutani, Kaushik Ghosh, et al.
The Journal of Pharmacology and Experimental Therapeutics|March 6, 2015
Evaluation of rosuvastatin as an organic anion transporting polypeptide (OATP) probe substrate: in vitro transport and in vivo disposition in cynomolgus monkeysHong Shen, Hong Su, Tongtong Liu, et al.
Pageof 14

Showing results (81-90 of 132) with videos related to

Sort By:
Pageof 14
Clinical Pharmacology and Therapeutics|December 16, 2022
Effect of Hepatic Impairment on OATP1B Activity: Quantitative Pharmacokinetic Analysis of Endogenous Biomarker and Substrate DrugsJian Lin, Emi Kimoto, Shinji Yamazaki, et al.
The Journal of Pharmacology and Experimental Therapeutics|January 29, 2005
Selective inhibition of dog hepatic CYP2B11 and CYP3A12Ping Lu, Suresh B Singh, Brian A Carr, et al.
British Journal of Clinical Pharmacology|May 20, 2014
Validation of 4β-hydroxycholesterol and evaluation of other endogenous biomarkers for the assessment of CYP3A activity in healthy subjectsSreeneeranj Kasichayanula, David W Boulton, Wen-Lin Luo, et al.
The Journal of Pharmacology and Experimental Therapeutics|January 13, 2018
Organic Anion Transporter 2 Mediates Hepatic Uptake of Tolbutamide, a CYP2C9 Probe DrugYi-An Bi, Sumathy Mathialagan, Laurie Tylaska, et al.
Drug Metabolism and Disposition: the Biological Fate of Chemicals|June 1, 2012
Evaluation of six proton pump inhibitors as inhibitors of various human cytochromes P450: focus on cytochrome P450 2C19Tatyana Zvyaga, Shu-Ying Chang, Cliff Chen, et al.
Journal of Clinical Pharmacology|January 12, 2019
Use of Physiologically Based Pharmacokinetic Modeling to Identify Physiological and Molecular Characteristics Driving Variability in Axitinib Exposure: A Fresh Approach to Precision Dosing in OncologyMichael J Sorich, Fayzah Mutlib, Madelé van Dyk, et al.
Journal of Extracellular Vesicles|May 28, 2026
Extracellular Vesicles as Enabling Biomarkers for New Approach Methodologies to Support the US Food and Drug Administration Modernization Act 3.0Andrew Rowland, Carl Kirkpatrick, A David Rodrigues, et al.
Drug Metabolism and Disposition: the Biological Fate of Chemicals|February 14, 2018
Comparison of Proteomic Quantification Approaches for Hepatic Drug Transporters: Multiplexed Global Quantitation Correlates with Targeted Proteomic QuantitationAnna Vildhede, Chuong Nguyen, Brian K Erickson, et al.
Drug Metabolism and Disposition: the Biological Fate of Chemicals|December 17, 2013
Expression and characterization of cynomolgus monkey cytochrome CYP3A4 in a novel human embryonic kidney cell-based mammalian systemSindhuja Selvakumar, Priyadeep Bhutani, Kaushik Ghosh, et al.
The Journal of Pharmacology and Experimental Therapeutics|March 6, 2015
Evaluation of rosuvastatin as an organic anion transporting polypeptide (OATP) probe substrate: in vitro transport and in vivo disposition in cynomolgus monkeysHong Shen, Hong Su, Tongtong Liu, et al.
Pageof 14